Suffering from Major Depressive Disorder (MDD)?


Take Part in an FDA Approved Study for Major Depressive Disorder (MDD) with the latest Deep TMS Technology

About BrainsWay Innovative Treatment (Deep TMS)

Brainsway* Deep TMS is an innovative, revolutionary technology for the treatment of different brain disorders. Deep TMS non-invasively stimulates the brain regions responsible for the smoking addiction using brief magnetic fields, at an amplitude similar to that used in magnetic resonance imaging (MRI) systems. The device has been cleared by the FDA for treating depression, and has been studied in over 60 clinical trials around the world.

The treatment does not entail systemic side effects, which are effects deriving from medication entering the bloodstream and circulating throughout the body.

Brainsway Deep TMS treatment requires only brief daily sessions over a few weeks, without indefinite or permanent medication intake.

About the Study

The study aims to demonstrate that the efficacy of the H7-Coil DTMS is at least as good as the efficacy of the FDA cleared, H1-Coil DTMS in subjects with MDD. The treatment will take place in leading medical centers around the world and is administered by experts. It entails no surgery, hospitalization or medications, and is based on 24 brief sessions of less than 20 minutes over a period of 4 weeks and additional 2 booster treatments at the 5 and 6 week follow-up visits. During the treatment, the patient is comfortably seated in a chair, and a cushioned helmet placed over the head generates brief magnetic fields.

Immediately after each session, patients can drive home independently and resume their daily routine. Patients can continue their current behavioral or medication treatment during the study. The study has been approved by the FDA.

Participant Criteria

Study participants should meet the following criteria: Aged 22-68, diagnosed with MDD with partial or no response to treatment and have not had any prior TMS treatment.

If you have been diagnosed with MDD, you may be eligible for the study.

Study Locations

Advanced Mental Health Care Inc. – Juno Beach, Florida, USA
Contact information: Elyssa Sisko, 561-2678876,

Advanced Mental Health Care Inc. – Royal Palm Beach, Florida, USA
Contact information: Elyssa Sisko, 561-2678876,

Advanced Mental Health Care Inc.- Palm Beach, Florida, USA
Contact information: Elyssa Sisko, 561-333-8884, / Aron Tendler, M.D., 561-3338884,

Dr. Laura Viner – Yellowbrick1560 Sherman Avenue, Ste. 400, Evanston, IL 60201 Telephone: 847-8691500 Fax: 847-8691515

Center for Addiction & Mental Health (CAMH) – Toronto, Canada
Contact information: Mawahib Semeralul, 416-535-8501 ext. 30210,

Medical University Of South Carolina (MUSC) – Charleston, South Carolina, USA Contact information: Scott Henderson, 843-792-5560,

Kadima Neuropsychiatry – San Diego, California, USA
Contact information: David Feifel, M.D., 858-412-4130,